10.24.12
Gilead
3Q Revenues: $2.4 billion (+14%)
3Q Earnings: $675.5 million (-9%)
YTD Revenues: $7.1 billion (+15%)
YTD Earnings: $1.8 billion (-14%)
Comments: Antiviral product sales increased 13% to $2.0 billion. Atripla sales increased 9% to $865.4 million. Sales of Truvada increased 8% to $804.2 million. Sales of Viread increased 11% to $214.9 million. Sales of Complera/Eviplera grew more than fivefold to $99.3 million. Sales of Stribild, which launched in the U.S. in August 2012, were $17.5 million. Cardiopulmonary product sales increased 24% to $200.1 million. Other product sales were $122.0 million, up 11%. Royalty, contract and other revenues were $68.6 million in the quarter, up 23%. R&D expenses were $465.8 million compared to $290.1 million in 3Q11.
3Q Revenues: $2.4 billion (+14%)
3Q Earnings: $675.5 million (-9%)
YTD Revenues: $7.1 billion (+15%)
YTD Earnings: $1.8 billion (-14%)
Comments: Antiviral product sales increased 13% to $2.0 billion. Atripla sales increased 9% to $865.4 million. Sales of Truvada increased 8% to $804.2 million. Sales of Viread increased 11% to $214.9 million. Sales of Complera/Eviplera grew more than fivefold to $99.3 million. Sales of Stribild, which launched in the U.S. in August 2012, were $17.5 million. Cardiopulmonary product sales increased 24% to $200.1 million. Other product sales were $122.0 million, up 11%. Royalty, contract and other revenues were $68.6 million in the quarter, up 23%. R&D expenses were $465.8 million compared to $290.1 million in 3Q11.